Massachusetts Financial Services Co. MA Sells 1,715,658 Shares of Pfizer Inc. $PFE

Key Points

• Massachusetts Financial Services Co. MA trimmed its Pfizer stake by 3.0% in Q4, selling 1,715,658 shares and ending the period with 55,873,002 shares (about 0.98% of Pfizer) valued at roughly $1.39 billion.
• Pfizer beat Q4 expectations, reporting $0.66 EPS versus $0.57 consensus and $17.56 billion in revenue (vs. $16.93 billion expected), though revenue was down 1.2% year‑over‑year.
• Analyst sentiment is mixed — price targets range from $26 to $35 and the stock carries an average rating of "Hold" with an average price target of $28.14, reflecting divergent views on near‑term upside.

Massachusetts Financial Services Co. MA lessened its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 55,873,002 shares of the biopharmaceutical company's stock after selling 1,715,658 shares during the quarter. Massachusetts Financial Services Co. MA owned approximately 0.98% of Pfizer worth $1,391,238,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Horizon Financial Services LLC raised its position in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 645 shares in the last quarter. YANKCOM Partnership bought a new position in Pfizer during the fourth quarter valued at approximately $28,000. Grey Fox Wealth Advisors LLC bought a new position in Pfizer during the third quarter valued at approximately $29,000. True Wealth Design LLC raised its position in Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 974 shares in the last quarter. Finally, Darwin Wealth Management LLC bought a new position in Pfizer during the second quarter valued at approximately $32,000. Institutional investors own 68.36% of the company's stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Morgan Stanley raised its price target to $28 and kept an "equal weight" rating, implying modest upside and signaling some confidence in near-term fundamentals. Morgan Stanley raises PFE price target (Benzinga)
• Positive Sentiment: MarketWatch noted a recent intraday uptick (but continued underperformance versus the broader market), which can attract short-term buyers looking for mean-reversion after pullbacks. Pfizer Inc. stock rises Wednesday (MarketWatch)
• Neutral Sentiment: Zacks flagged Pfizer as a "trending" stock, meaning elevated retail/institutional attention — this can increase volatility but doesn’t by itself indicate direction. Pfizer is a trending stock (Zacks)
• Neutral Sentiment: Coverage pieces (Yahoo/MSN) are re-examining Q4 earnings, one-year performance and valuation after a strong one‑year gain; these narratives shape whether investors view PFE as fairly valued or still a buy. Is Pfizer Offering Value (Yahoo) Q4 earnings highs and lows (MSN)
• Neutral Sentiment: Pfizer announced its virtual Annual Meeting on April 23; routine corporate governance items can temper short-term trading but are unlikely to change fundamentals. Annual meeting webcast (BusinessWire)
• Neutral Sentiment: Industry research on the biopharmaceutical CXO market cites Pfizer among large players navigating outsourcing and supply-chain trends — a background macro theme that could help longer-term margins but is not an immediate catalyst. Biopharmaceutical CXO market report (Yahoo/GlobeNewswire)
• Negative Sentiment: Bank of America cut its price target to $26 and moved to "neutral," signaling downside risk and adding selling pressure from model-driven desks. Bank of America lowers PFE PT (Benzinga)
• Negative Sentiment: Zacks ran a comparative piece showing AbbVie (ABBV) pulling ahead on strong growth from Skyrizi and Rinvoq, underscoring competitive headwinds in immunology that could pressure Pfizer’s growth multiple. AbbVie vs Pfizer growth comparison (Zacks)
• Negative Sentiment: Coverage explaining why Pfizer tumbled earlier in the week highlights mixed near-term signals (analyst downgrades, rotation to other healthcare names), which can prolong weak sentiment even after small positive data points. Why Pfizer stock tumbled (Yahoo)

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on PFE shares. Argus raised shares of Pfizer from a "hold" rating to a "buy" rating and set a $35.00 price objective on the stock in a research report on Monday, March 2nd. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research report on Thursday, January 22nd. Bank of America dropped their price target on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research report on Thursday. Morgan Stanley lifted their price target on shares of Pfizer from $27.00 to $28.00 and gave the company an "equal weight" rating in a research report on Friday. Finally, HSBC lifted their price target on shares of Pfizer from $29.00 to $32.00 and gave the company a "buy" rating in a research report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $28.14.

Pfizer Trading Down 1.2%

NYSE:PFE opened at $26.91 on Friday. Pfizer Inc. has a 12 month low of $21.28 and a 12 month high of $28.75. The firm has a market cap of $152.99 billion, a price-to-earnings ratio of 19.78 and a beta of 0.43. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The company's 50 day moving average is $27.20 and its 200-day moving average is $25.93.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same quarter in the previous year, the firm posted $0.63 earnings per share. Pfizer's revenue was down 1.2% compared to the same quarter last year. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.